Jifu Medical Raises ￥100M in Series C

According to PEdaily.cn, Shenzhen Zifu Medical Technology Co., Ltd. (hereinafter referred to as "Zifu Medical") has recently raised hundreds of millions of yuan in a Series C financing. This round was led by Greenwoods Investment, with additional support from Bojiang Capital, TopoScend Capital, EFUNG Investment and Big Dipper Investment. 

The funds raised will be used to further promote the R&D, marketing and expansion of production of Zifu Medical's products for non-invasive test and intelligent diagnosis in the digestive tract. Prior to this, Zifu Medical also completed the Series A and Series B financing led by Dingxin Capital in 2017 and 2019.

Founded in 2011, Zifu Medical is a state-level high-tech company focusing on the R&D, production, sales and related service of high-end medical devices placed within the gastrointestinal tract. It has innovative technological achievements in the field of digestive endoscopy, such as a new generation of magnetic-controlled capsule endoscope system and capsule endoscope system.

Headquartered in Nanshan District, Shenzhen, Zifu Medical has set up a modern production base in Shenzhen Guangming District and established a medical device quality management system, which has obtained the GMP and ISO13485 certification.

Zifu Medical has a professional R&D team and an international R&D management platform. Adhering to independent innovation, the series products of magnetic-controlled capsule endoscope system namely "Da Sheng" have obtained the approval of class III medical device registration by the National Medical Products Administration (NMPA) and EC Certificate by the European Union in December 2019.

Greenwoods Investment is a private equity and venture capital firm focused on early-stage investments. The total AUM of Greenwoods exceeds over 25 billion RMB. Greenwoods Investment focuses on opportunities in consumer and modern services, medical, pharmaceutical and healthcare, TMT, and so on.

Founded in 2005, Bojiang Capital is committed to investment in TMT, big data, artificial intelligence (AI), high-end manufacturing, enterprise services, financial science and technology, new materials, and healthcare and culture in the early and growth stage.